Rationale: Long non-coding RNAs (lncRNAs) represent a novel class of molecules regulating gene expression. LncRNAs are present in body fluids, but their potential as biomarkers was never investigated in cardiovascular disease.
INTRODUCTION
The existence of extracellular nucleic acids is known for several decades. 1 A diagnostic potential of RNA in body fluids was realized after the initial discovery of specific extracellular RNAs in plasma of cancer patients. 2, 3 Long non-coding RNAs (lncRNAs) are conventionally defined as a transcript longer than 200 nucleotides in length with lack of protein-coding capability. 4 Recognition of the roles of lncRNAs in human disease has unveiled new mechanistic understanding and will lead to novel diagnostic and therapeutic approaches. 5 LncRNAs often form secondary structures, and relatively more stable, which facilitate their detection as free nucleic acids in body fluids such as urine and blood. 6 Due to their wellestablished association with various cancers, lncRNAs have been previously investigated for their potential role as cancer biomarkers in body fluids. A prostate specific lincRNA PCA3 in urine has been identified as the most specific biomarker for the detection of prostate cancer with higher specificity compared to the widely used PSA (prostate-specific antigen) test. 7, 8 The PCA3 assay has been approved for detection of prostate cancer, and is readily available for clinical use. In addition, several other studies have highlighted the potential of lncRNA as candidate biomarkers for the detection of various cancers. [9] [10] [11] Although numerous studies (albeit with relatively small number of patients, with few exceptions) have investigated small RNAs such as microRNAs (miRNAs) as potential biomarkers for heart failure 12 , the diagnostic utility of circulating lncRNAs in heart diseases has never been investigated. We here explored the potential use of circulating lncRNAs in plasma as prognostic biomarkers for heart failure. The initial lncRNA screening was performed according to the level of left ventricular (LV) remodeling in a prospective echocardiographic study of patients after myocardial infarction (MI). LV remodeling, which remains frequent in modern clinical practice DOI : 10.1161/CIRCRESAHA.114.303915 4 Universitaire de Lille) approved the study; written informed consent was obtained from all patients. The design of this study has been previously published in detail. 16, 17 We first analyzed lncRNAs levels in 344 consecutive patients included from January 2006 to May 2010 (referred to as the HF cohort study). A follow-up was performed after three years to assess clinical outcome. For patient characteristics see Table  2 . The prognostic value of the lncRNA was further assessed in an independent population of 198 patients included between November 1998 and December 2005 who underwent a prognostic evaluation including a clinical evaluation, echocardiography, cardiopulmonary exercise tests, and BNP measurement. (referred to as the HF case/control study). We selected 99 patients who died from cardiovascular death within three years after prognostic evaluation (cases); these 99 patients were matched (for age, sex, and HF etiology) with 99 HF patients who were alive after three years (controls). For patient characteristics see Table 3 .
RNA isolation from plasma, microarray analysis of lncRNAs and LncRNA stability testings. This has been described in the supplemental Material.
Statistical analysis.
Statistical analyses were performed using R Statistical Package version 3.0. Results are presented as the mean ± SD or number (percentages) of patients. In all statistical analyses, lncRNAs levels were logtransformed by taking the base two logarithm to account for the skewness of their distributions. Continuous variables were compared using unpaired Student's t-test. Discrete variables were compared using 2 analysis. A p value <0.05 was considered statistically significant. Multivariate logistic regression was used to calculate odds ratios (OR) and corresponding 95% confidence intervals. OR were reported for a standard deviation increase. The associations of the baseline levels of the 7 candidate lncRNAs with LV-remodeling in the REVE-2 study were assessed using a logistic regression adjusted for age, sex, and LVEDV at baseline. In both HF populations, cardiovascular death was defined as deaths from cardiovascular causes, urgent transplantations (defined as United Network for Organ Sharing status one), or urgent left ventricular assist device implantation. The association of the selected lncRNA with the risk of cardiovascular death was assessed using a logistic regression adjusted for age, sex, ischemic etiology, and diabetes. In the casecontrol study, the independent prognostic value of the selected lncRNA was assessed by a logistic regression adjusted for age, sex, ischemic etiology, diabetes, NYHA class, LVEF, BNP, and peak exercise oxygen consumption (Peak VO 2 ). To illustrate the prognostic impact of the selected lncRNA in HF patients, its levels were categorized into quartiles. Finally, we examined whether the selected lncRNA improved the prediction of cardiovascular death when added to a model with age, gender, heart failure etiology, diabetes melitus, NYHA class, LVEF, VO2 and BNP, by computing difference in C-index (Δ C-index), continuous net reclassification improvement (cNRI) and integrated discrimination improvement (IDI).
RESULTS

Levels of circulating lncRNAs are altered during the early stage of post-MI LV-remodeling.
LncRNA arrays were performed from RNA derived from plasma of patients included in the LVremodeling study ( Figure 1A ,B). The characteristics of the 246 patients included in this study are summarized in Table 1 . One-year echocardiographic follow-up was completed for 226 (92%) patients. LVremodeling, defined as a >20% change in LVEDV between baseline and 12 months, occurred in 87 (38.5%) patients. From this population, we selected 15 male patients with high LV-remodeling (change in LVEDV = 73±19%) and 15 male patients without LV-remodeling (change in LVEDV = -10±10%) with the same LVEDV baseline at discharge (high-remodelers: 49±11 ml/m 2 vs 49±12 ml/m 2 in non-remodelers). In an attempt to study alterations in circulating lncRNAs at early stage of post-MI LV-remodeling, microarrays were performed on RNA from plasma of these 30 patients at baseline. DOI : 10.1161/CIRCRESAHA.114. 303915 5 Hierarchical clustering analysis clearly distinguished the two groups of patients based on a specific signature of detectable and significantly regulated circulating lncRNAs ( Figure 1B) . A total of 768 lncRNA transcripts were specifically de-regulated (550 lncRNA transcripts up-regulated and 218 lncRNA transcripts down-regulated; each p<0.05) in patients that will develop LV-remodeling ( Figure 1B ; Online Table I ). Filtering of all deregulated transcripts for high signal intensity (≥9) and at least 3-fold deregulation yielded 15 lncRNA candidates, of which 7 could be consistently amplified in all individual samples that were used for microarrays. When the abundance of all detectable lncRNAs was correlated to their chromosomal origins, the highest percentage (77.78%) of high abundant lncRNAs (signal intensity > 9) originated from the mitochondrial genome (chromosome M) (compared to 1.3 to 4.3% for somatic and sex-chromosomes). Thus, the majority of mitochondrial lncRNAs was abundantly present in plasma (Online Table II ). Interestingly, all seven lncRNAs that could be consistently amplified in all individual samples originate from the mitochondrial genome and all these lncRNAs were significantly down-regulated (p<0.05) in the initial microarray analysis. The expression level of these seven candidate lncRNAs was then assessed by independent real-time PCR in the entire study population of 246 patients at baseline. Levels of these seven lncRNAs were positively correlated with each other (Online Table III Figure 1C ). Since these both lncRNAs levels were positively correlated (Online Table III) , we selected uc022bqs.1 (which had the greatest association with LV-remodeling) for further analyses. Because of its properties we referred this lncRNA as LIPCAR in subsequent sections of the manuscript (Long Intergenic non-coding RNA Predicting CArdiac Remodeling).
LIPCAR levels are increased during late stages of post-MI remodeling.
We next longitudinally studied the level of LIPCAR in plasma samples obtained one, three and 12 months after MI in the patients of the REVE-2 cohort. In the overall study population, there was an increase in LIPCAR levels throughout the one year follow-up period. Importantly, as illustrated in Figure 2A , when assessed at one, three and 12 months, LIPCAR levels were significantly higher in patients developing LVremodeling. Thus, in patients with LV-remodeling, circulating levels of LIPCAR are down-regulated at baseline, but significantly up-regulated later on during the development of heart failure (HF).
LIPCAR levels are elevated in chronic heart failure patients.
Since LIPCAR was upregulated in the late stages of patients developing LV-remodeling post-MI, we hypothesized that its circulating levels could also be elevated in patients with chronic HF. This was tested in another independent cohort of 344 patients with systolic HF (see Table 2 for patient characteristics). These patients had similar age and sex characteristics compared to the patients of the LVremodeling study; they also received angiotensin-converting enzyme inhibitors and beta-blockers in most cases. HF was of ischemic etiology in about half of the cases. These patients had more advanced disease than the patients of the LV-remodeling study as shown by their lower LV ejection fraction. As illustrated in Figure 2B , LIPCAR levels were even higher in chronic HF than in patients with ongoing LV-remodeling one year after MI; this was not only apparent for patients with ischemic HF but also for patients with non ischemic HF (both P <0.0001 vs patients with LV-remodeling one year after MI). We next studied whether LIPCAR levels may be associated with the risk of future cardiovascular events in chronic HF patients. During a three-year clinical follow-up, 39 HF patients with LIPCAR measurements at inclusion died from cardiovascular causes, while 254 were still alive after three years. LIPCAR levels at inclusion were significantly associated with the risk of cardiovascular death (OR (adjusted for age, sex, ischemic etiology, and diabetes mellitus) = 1. 
LIPCAR as a prognostic indicator for chronic HF.
Since the observation that elevated LIPCAR levels may be associated with future cardiovascular death was derived from a population with a limited number of events, we further studied the prognostic value of this potential biomarker in a third population of chronic systolic HF patients. As explained earlier, this was a case-control study in which cases died from cardiovascular death within three years after prognostic evaluation, while controls were still alive after three years. As shown in Table 3 , cases had higher NYHA class and BNP levels, and lower Peak VO 2 . As shown in Figure 2C , LIPCAR levels at the time of prognostic evaluation were higher in case patients than in control patients (P<0.0001). Compared with patients in the first quartile for LIPCAR levels, patients in the third and fourth quartiles had increased cardiovascular mortality (OR = 6.58 [2.76-16 .67], and 13.23 [5.19-36.8] , respectively, both P<0.0001) ( Table 4 ). In a model adjusting for age, sex, ischemic etiology, diabetes mellitus, NYHA class, LVEF, BNP, and Peak VO 2 , the level of LIPCAR used as a continuous variable was an independent predictor of threeyear cardiovascular mortality with an adjusted OR of 4.16 [2.67-6 .90] (P<0.0001); similar results were obtained when LIPCAR levels were categorized into quartiles (third vs first quartile, OR = 17.12 [5.19-66 .61] (P<0.0001); fourth vs first quartile, OR = 32.58 [9.62-131 .00] (P<0.0001). Finally, Δ C-index, cNRI and IDI also demonstrated that the level of LIPCAR improved the prediction of cardiovascular death (Online Table IV ).
DISCUSSION
Cardiovascular diseases are the leading cause of death. 18 Despite advances in understanding and treatment of HF, it still has a poor prognosis. 19 Genome-wide screening approaches provided new opportunities to develop novel diagnostic or prognostic markers and to identify novel therapeutic targets. For example, genomic mapping studies have identified lncRNA PCA3 as a prostate cancer specific gene 20 which was later found to be the most sensitive biomarker for detection of prostate cancer. 7, 8 Several lncRNA-based biomarkers were identified in subsequent studies for detection of different cancers. [9] [10] [11] However, such clinical studies were never performed in cardiovascular diseases. A recent study has indicated that the myocardial transcriptome is dynamically regulated in advanced heart failure and the expression profiles of lncRNAs can discriminate failing hearts of different pathologies. 21 In the present study we performed a genome-wide screen to identify lncRNAs that are differentially present in plasma from patients with or without severe left-ventricular remodeling post-MI. Hierarchical clustering analysis distinguished the high remodeling from non remodeling patients based on the circulating lncRNA signature. Interestingly, almost all lncRNAs that originate from mitochondrial genome were downregulated in the microarray analysis at baseline in patients who presented high LV-remodeling 12 months after MI. At least two out of these seven lncRNA candidates were found to be significantly down-regulated in patients with severe LV-remodeling after testing in the entire patient cohort, with the strongest association found for uc022bqs.1. Surprisingly, the level of uc022bqs.1 (here referred as LIPCAR) was significantly up-regulated in subsequent samples serially collected at one, three, and 12 months after MI. Using another independent patient cohort, we found that the level of LIPCAR is up-regulated in patients with chronic HF independently of the etiology and that higher LIPCAR levels were associated with a higher risk of cardiovascular death. The potential of this lncRNA in predicting mortality in HF patients was further investigated in another population of patients with systolic HF. Results indicate that higher LIPCAR levels are strongly associated with cardiovascular mortality in HF patients, and that LIPCAR measurement provides independent information on top of classic risk stratification. Results from all patient chohorts are summarized in Online Rather than performing microarrays directly in HF patients, our choice was to screen lncRNAs associated with LV-remodeling after MI. The degree of LV-remodeling can be easily measured using serial imaging techniques and is a major determinant of ischemic HF. 14 In addition, such a strategy allowed us to avoid imbalances in baseline medications between groups since most patients received maximal treatment regardless of the level of remodeling. The fact that patients with chronic HF had higher levels of LIPCAR than patients with LV-remodeling is concordant with the more advanced disease of the HF populations.
Recently it was found that mitochondrial lncRNAs contribute to more than 70% of the total lncRNA pool of the human left ventricle 21 , suggesting that a good proportion of mitochondrial lncRNAs detected in circulation might come from the heart. However, at the moment it is not clear whether LIPCAR simply represents ongoing cellular damage or any other pathological processes in cardiomyocytes or serves any specific function in heart. Deep-sequencing based characterization of exosomal RNA from human plasma revealed that at more than 3% of total exosomal RNA is represented by lncRNAs 22 . Therefore it is tempting to speculate that similar to miRNAs, lncRNAs or parts of lncRNAs may also circulate in blood in association with microvesicles or bound to proteins.
However a potential function of the mitochondrial lncRNA LIPCAR in regulating mitochondrial pathways such as oxidative phosphorylation, and mechanism of lncRNA circulation in blood needs to be explored in future studies. patients with a first anterior wall Q-wave MI screened for LV-remodeling during the 1-year post-MI period and collected over four different time points (baseline, after one, three and 12 months), 344 patients with chronic heart failure, and 198 patients from a case/control study of patients with chronic heart failure were employed in the present study. This approach identified LIPCAR, a long intergenic non coding RNA predicting cardiac remodeling and survival of heart failure patients. (1) 87 (38.5% (2) ) LV indicates left ventricular; SD, standard deviation; IU, international units; HF, heart failure ; EF, ejection fraction; ACE, angiotensin-converting enzyme; EDV, end-diastolic volume.
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Novelty and Significance
What Is Known?
 Long non-coding RNAs (lncRNAs) regulate several cellular processes including those involved in cardiovascular development.
 LncRNAs have been detected in plasma of cancer patients and may be useful biomarkers of carcinogenesis.
What New Information Does This Article Contribute?
 Mitochondria-derived lncRNAs are present in the plasma of patients with cardiovascular disease.
 The mitochondria-derived lncRNA LIPCAR is associated with future development of cardiac remodeling in patients who had an episode of acute myocardial infarction.
 LIPCAR is independently associated with cardiovascular mortality in patients with chronic heart failure.
Few biomarkers predict the future development of cardiac remodeling and death. Therefore, we studied the potential role of circulating long non-coding RNAs (lncRNAs) as clinically useful biomarkers. Global transcriptomic analyses identified the mitochondrial lncRNA uc022bqs.1 (named as LIPCAR) as a predictor of future development of pathologic cardiac remodeling in patients who had an episode of myocardial infarction. LIPCAR levels were also associated with future cardiovascular deaths in heart failure patients independent of other predictors. LncRNAs likely have an important regulatory role in cardiac biology and they might be useful and novel biomarkers of cardiovascular disease development and prognosis. 
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Supplemental methods
RNA isolation from plasma
For each patient, plasma was collected and processed as described earlier. 1 Thus, RNA was isolated from 1526 samples (246 from the REVE 2 study collected over four different time points, 344 from the systolic HF cohort and 198 from the systolic HF case/control study) using the miRNeasy 96 Kit (Qiagen, #217061). As an internal spike-in control, Caenorhabditis elegans cel-miR-39 was added during the isolation process. Quality and integrity of the isolated RNA was verified by NanoDrop (Thermo scientific) and Bioanalyzer (Agilent). OD260/280 ratio ranged between 1.68 to 1.8 and RIN numbers ranged between 7.1 to 7.8.
Microarray analysis of lncRNAs
For the initial lncRNA screening, plasma RNA was isolated from 15 male patients from the REVE2 cohort showing significant LV-remodeling 12 months after myocardial infarction and 15 male patients with no LV-remodeling (as defined earlier). Six RNA samples were obtained from the 30 patients by pooling RNA from five patients within one group as 'one sample'. Thus, we generated three pooled RNA samples from 15 patients with LV-remodeling and three from patients without LV-remodeling. These pools were subjected to microarray-based global transcriptome analysis. RNA was first pre-amplified and then subjected to microarrays (Arraystar Human LncRNA array; version 2.0), which allow simultaneous detection of 33,045 lncRNAs. To define a potential good biomarker candidate lncRNA, we chose the following strategy: we first sorted all lncRNA transcripts that were included in the microarrays according to their average signal intensity. The signal intensity for each lncRNA transcript ranged between five (lowest value) to 17 (highest value). Only 1.3 to 4.3% of all lncRNA transcripts that are expressed from all somatic and sex chromosomes showed a signal intensity of >9 in plasma (Online Table II ). LncRNA detection was next validated by real time PCR. For this purpose, the isolated RNA was reverse transcribed with random primers (lncRNAs). Specific lncRNAs were amplified using primers listed in Online Table VI. C.elegans-miR-39 was amplified using a TaqMan assay as a normalization control.
LncRNA stability testings
We tested stable detection of seven different lncRNAs in plasma of three healthy controls. This included testing lncRNA detection in plasma directly after blood withdrawal and keeping plasma at room temperature for 4h, 8h and 24h. In addition we tested the influence of four repetitive freeze/thaw cycles on lncRNA expression. Overall, in all samples all seven investigated lncRNAs could be stably detected with no effects of keeping at room temperature or repetitive freeze/thaw cycles (Online Figure I) . Detection of seven different lncRNAs in plasma of three healthy controls. RNA was isolated from fresh plasma (0h) as well as from plasma kept on room temperature for up to 24h and from plasma subjected to 4 freeze/thaw cycles.
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